ELITE PHARMACEUTICALS INC /NV/ Income Statement
ELTP|14 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
Revenue has grown at a 31.4% compound annual rate over the past 13 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $84.0M | $56.6M | $34.2M | $32.3M | $25.4M | $18.0M | $7.6M | $7.5M | $9.6M | $12.5M | $5.0M | $3.4M | $2.4M |
| Cost of Revenue | - | $44.0M | $30.3M | $17.6M | $17.5M | $13.5M | $10.0M | $4.7M | $3.5M | $5.9M | $4.5M | $3.0M | $2.3M | $1.0M |
| Gross Profit | - | $40.1M | $26.4M | $16.6M | $14.8M | $11.9M | $8.0M | $2.9M | $3.9M | $3.7M | $8.0M | $2.0M | $1.1M | $1.4M |
| SG&A Expense | - | $9.0M | $7.1M | $5.1M | $4.5M | $3.3M | $3.3M | $3.1M | $2.3M | $2.1M | $2.9M | $2.9M | $1.5M | $1.4M |
| R&D Expense | - | $8.0M | $6.9M | $6.2M | $4.1M | $5.1M | $5.5M | $7.6M | $9.6M | $8.3M | $12.4M | $14.7M | $975.3K | $1.7M |
| Operating Income | - | $19.6M | $10.8M | $3.7M | $5.1M | $2.1M | -$2.3M | -$9.2M | -$9.1M | -$7.4M | -$8.3M | -$16.5M | -$1.6M | -$2.0M |
| Interest Expense | - | $128.2K | $588.6K | $1.1M | $191.8K | $259.6K | $355.9K | $369.2K | $335.5K | $238.2K | $280.7K | $287.2K | $253.7K | $229.6K |
| Income Tax | - | $4.3M | -$19.6M | $424.0K | -$1.7M | - | -$676.0K | -$676.0K | -$1.0M | -$1.9M | -$520.5K | -$3.2K | - | - |
| Net Income | - | -$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | -$2.2M | -$9.3M | -$3.7M | $3.8M | -$683.0K | $5.2M | $1.5M | -$15.1M |
| EPS (Basic) | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 | -$0.01 | $0.00 | -$0.01 | $0.05 | -$0.21 | -$0.21 | $0.00 | -$0.06 | - |
| EPS (Diluted) | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.21 | -$0.21 | $0.00 | -$0.06 | -$0.14 |
| Shares Outstanding | 1.1B | 1.0B | 1.0B | 1.0B | 840.4M | 824.8M | 802.5M | 927.9M | 711.4M | 631.1M | 560.1M | 374.4M | 331.6M | 180.5M |
| Gross Margin | - | 47.7% | 46.6% | 48.6% | 45.9% | 46.8% | 44.3% | 37.9% | 52.9% | 38.8% | 64.1% | 39.9% | 32.0% | 58.2% |
| Operating Margin | - | 23.3% | 19.1% | 10.8% | 15.7% | 8.3% | -12.7% | -121.0% | -121.4% | -76.3% | -66.5% | -329.1% | -45.9% | -81.1% |
| Profit Margin | - | -5.1% | 35.5% | 10.4% | 27.6% | 20.1% | -12.4% | -122.6% | -49.3% | 39.5% | -5.5% | 104.1% | 43.7% | -621.2% |